Status:
UNKNOWN
Prostate Cancer - Localized Adenocarcinoma Proton Therapy
Lead Sponsor:
National Cancer Center, Korea
Conditions:
Prostate Adenocarcinoma
Eligibility:
MALE
Phase:
NA
Brief Summary
A Phase II Randomized Trial of Hypofractionated Proton Therapy in Patients With A Localized Prostate Adenocarcinoma
Detailed Description
For Proton therapy with prostate adenocarcinoma patients. Arm 1: Proton therapy 3CGE x 20days = Total 60 CGE for 4 weeks. Arm 2: Proton therapy 4.7CGE x 10days = Total 47 CGE for 2 weeks.
Eligibility Criteria
Inclusion
- Biopsy proven prostate adenocarcinoma Stage: T1-T2cN0M0
- ECOG performance status:0-1
- Signed study specific informed consent prior to study entry.
Exclusion
- Postoperative residual or recurrent tumor
- Evidence of distant metastasis previous irradiation for the tumor in the same location
- Adjuvant anti-androgenic hormonal therapy High risk group (NCCN guide line)
Key Trial Info
Start Date :
May 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
156 Patients enrolled
Trial Details
Trial ID
NCT03285815
Start Date
May 1 2016
End Date
December 1 2025
Last Update
September 18 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kwanho Cho
Ilsan, Gyenggi-do, South Korea